Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats).
Experiments on adult Wistar rats showed that injection of beta-amyloid25-35 (2 microg) into Meynert basal nuclei caused long-term memory deficiency which was detected 24 days after this injection by the memory trace retrieval in conditioned passive avoidance reflex (CPAR). The effects of noopept, an original nootropic and neuroprotective dipeptide, on the severity of this cognitive deficiency were studied. Preventive (for 7 days before the injury) intraperitoneal injections of noopept in a dose of 0.5 mg/kg completely prevented mnestic disorders under conditions of this model. Noopept exhibited a significant normalizing effect, if the treatment was started 15 days after the injury, when neurodegenerative changes in the basal nuclei, cortex, and hippocampus were still acutely pronounced. The mechanisms of this effect of the drug are studied, including, in addition to the choline-positive effect, its multicomponent neuroprotective effect and stimulation of production of antibodies to beta-amyloid25-35. Noopept efficiency in many models of Alzheimer disease, its high bioavailability and low toxicity suggest this dipeptide for further studies as a potential agent for the treatment of this condition (initial and moderate phases).
Ostrovskaya
R U
RU
Laboratory of Psychopharmacology, V. V. Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia. rita@nicemail.ru
Belnik
A P
AP
Storozheva
Z I
ZI
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D020532:Basal Nucleus of Meynert / Q000187:drug effects* / Q000502:physiology; D004151:Dipeptides / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000517:prevention & control; D018697:Nootropic Agents / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D016229:Amyloid beta-Peptides; D004151:Dipeptides; D018697:Nootropic Agents; D010446:Peptide Fragments; C074636:amyloid beta-protein (25-35); C103871:ethyl phenylacetyl-Pro-Gly